Pure Global
NCT06356948

Rate of Tranexamic Acid Administration on Blood Pressure (RateTXA) Study.

The Effect of Tranexamic Acid Rate of Administration on Blood Pressure in Healthy Pregnant Women Scheduled for Elective Cesarean Delivery Under Spinal Anesthesia - A Prospective, Randomized, Double-blind, Non-inferiority Trial.
University of British Columbia·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Tranexamic Acid (TXA)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of British Columbia
Location
Vancouver, Canada
Timeline & enrollment
Phase
Phase 4
Start date
Mar 30, 2024
End date
Dec 30, 2027
Enrollment
110 participants
Primary outcome

Change in systolic blood pressure from baseline over 15 minutes post-TXA administration between groups.

Summary

Tranexamic acid is a well-established treatment for post-partum hemorrhage. This study aims
 to examine the effect of tranexamic acid administration rates on blood pressure changes over
 1 minute compared to 10 minutes in healthy pregnant patients scheduled for cesarean delivery.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06356948
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06356948 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of British Columbia and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 110 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.